Benjamin Goodchild

Paul, Weiss is advising UK-based GSK plc in its proposed acquisition of an investigational molecule used to treat autoimmune disease from Chimagen Biosciences, a China-based privately held biotechnology company. Under the terms of the agreement, GSK will pay $300 million up front to acquire the full global rights to the molecule, CMG1A46. Chimagen will also be eligible to receive success-based development and commercial milestone payments for CMG1A46 totaling $550 million. GSK plans to develop and commercialize CMG1A46, with a focus on certain types of lupus, with potential to expand into related autoimmune diseases. The transaction is subject to customary closing conditions and regulatory approvals. The Paul, Weiss team is led by partners Krishna Veeraraghavan, Benjamin Goodchild, Jonathan Ashtor and Bonnie Chen, and includes corporate partner Judie Ng Shortell and counsel Jack Sun; tax partner Cian O’Connor; and litigation partners Geoffrey Chepiga and Crystal Parker.

Oct 29

1 min

Paul, Weiss is advising Strategic Value Partners, LLC (SVP), a global alternative investment firm with approximately $19 billion of assets under management, in the all-cash acquisition by SVP-managed funds of Revelyst for an enterprise value of $1.125 billion. A segment of Vista Outdoor Inc., Revelyst is a collective of world-class maker brands that design and manufacture performance gear and precision technologies. The transaction is expected to close by January 2025, subject to the completion of the sale of Vista’s Kinetic Group division to Czechoslovak Group a.s., as well as the receipt of necessary regulatory approvals and other customary closing conditions. The Paul, Weiss team is led by corporate partners Robert Kindler, Benjamin Goodchild and Nickolas Bogdanovich and includes, among others, partners Matthew Leist, Jeffrey Marell, Eric Wedel, Christodoulos Kaoutzanis, Ben Steadman, Brian Janson, John Kennedy and Patricia Vaz de Almeida and counsel Anya Richter Hodes, Peter Bang, Nathan Mitchell, Jason Tyler and Frances Mi; tax partner Robert Holo and counsel Alyssa Wolpin and Patrick Karsnitz; executive compensation partners Andrea Wahlquist Brown and Jean McLoughlin and counsel Sasha Belinkie, Jake Glazeski and Bruce Goldberger; antitrust partners Richard Pepper, Scott Sher, Annie Herdman and Marta Kelly and counsel Todd Hahn, Yuni Sobel and John Magruder; intellectual property partner Jonathan Ashtor and counsel Brianna van Kan; litigation partners Andre Bouchard, Geoffrey Chepiga, Lewis Clayton, and John Carlin and counsel Audrey Paquet and Robert Kravitz; restructuring partners Andrew Rosenberg and Joseph Graham and counsel Claudia Tobler; real estate partner Peter Fisch; and environmental counsel William O’Brien.

Oct 4

1 min

Paul, Weiss is advising Envestnet, Inc., a leading provider of integrated technology, intelligent data and wealth solutions, in its $4.5 billion take-private acquisition by Bain Capital. Under the terms of the agreement, Envestnet shareholders will receive $63.15 in cash for each share of common stock they own. Strategic partners BlackRock, Fidelity Investments, Franklin Templeton and State Street Global Advisors have committed to investing in the proposed transaction and will hold minority positions in the private company upon the deal’s completion. Reverence Capital will also participate in the transaction, which is expected to close in the fourth quarter of 2024, subject to customary closing conditions, including stockholder and regulatory approvals. The Paul, Weiss team is led by partners Robert Kindler, Benjamin Goodchild and Andre Bouchard, and includes corporate partners Ben Steadman, Jarryd Anderson, Timothy Cruickshank, Manuel Frey, Anastasia Peterson, Aaron Schlaphoff, Eric Wedel, Brian Janson and Patricia Vaz de Almeida, and counsel Lyudmila Bondarenko, Arik Hirschfeld, Nathan Mitchell, Jason Tyler, Daniel Meade and David Gerst; executive compensation partners Jarrett Hoffman and Jean McLoughlin; antitrust partners Scott Sher and Ross Ferguson; litigation partners Christopher Wilson, Geoffrey Chepiga and John Carlin, and counsel Audrey Paquet; intellectual property partner Jonathan Ashtor; and tax partner Brian Krause.

Jul 12

1 min

Paul, Weiss is advising Eli Lilly and Company in its acquisition of Orna Therapeutics, Inc., a biotechnology company dedicated to engineering immune cells in vivo. Under the terms of the agreement, Lilly will acquire Orna for up to $2.4 billion in cash, inclusive of an upfront payment and subsequent payments upon achievement of certain clinical development milestones. Orna is advancing a new class of therapeutics designed to allow the patient’s own body to generate cell therapies that can treat underlying disease. The Paul, Weiss team is led by partners Krishna Veeraraghavan, Chelsea Darnell and Jeffrey Osterman, and includes corporate partner Benjamin Goodchild; intellectual property partner Meggin Bednarczyk; tax partner Scott Sontag; executive compensation partner Jarrett Hoffman; real estate partner Peter Fisch and counsel Ruobing Chen; and litigation partner Elizabeth Weiswasser and counsel Audrey Paquet.

Feb 9

1 min